Amgen taking different path to weight loss windfall : vimars

Amgen taking different path to weight loss windfall

The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly's highly-effective Zepbound, but Amgen is taking a unique approach. Zepbound, which promotes the most weight loss among treatment options currently on the market, stimulates two different gut hormones to fight obesity, GLP-1 and GIP. Amgen's most advanced experimental candidate activates GLP-1 while blocking GIP.

Related Keywords

Deena Beasley , Ruth Gimeno , Narimon Honarpour , Louis Aronne , Lilly Zepbound , Morningstar Anderson , Eli Lilly , Karen Anderson , Caroline Apovian , Caroline Humer , Reuters , Amgen , Novo Nordisk , Women Hospital Center , Biotech Index , Structure Therapeutics , Carmot Technologies , Weill Cornell Medicine , Hospital Center , Weight Management , Reporting By Deena Beasley , Bill Berkrot , Weight Loss , Lip , Weight Loss Drug , Ip Receptor ,

© 2025 Vimarsana